Clinical Trial Search

Primary: Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score — -67.5; -63.5; -11.7 Percentage change from Baseline

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 91; 31; 26 Participants

Primary: Percentage of Participants With a Solicited Injection-site Adverse Event After Vaccination 1 — 4.6; 3.3; 57.2; 51.3 Percentage of Participants

Primary: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period — 0.350; 0.241; 0.181 relapses/year — p=<0.0001

Primary: Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12 — 13.78; 10.64 Lesions — p=0.0051

Primary: Minimal Effective Dose of Hyperbaric Bupivacaine — 1.9 milligrams

Primary: Nicotine Withdrawal and Craving — p=0.07

Primary: Responder Rate — 159; 165; 163; 5 Participants — p=<0.0001

Primary: Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts — 70; 116 Participants

Primary: Cumulative Rate of Spontaneous Abortions Occurring on or Before 12 Weeks Post-oocyte Retrieval — 7.4 percentage of participants

Primary: Disease-free Survival (DFS) With Pazopanib 600 mg Daily Initial Dose vs. Placebo — NA; NA months — p=0.1649

Primary: The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit). — 42 Participants

Primary: Change From Baseline to Week 26 in Absolute Millilitre (mL) Forced Vital Capacity (FVC) — 128.78 Milliliter (mL)

Primary: iGFR at the End of the Wash-out Period — 61.2; 61.2 ml/min/1.73 m^2 — p=0.999

Primary: Subjects With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 — 95; 14 Participants — p=0.002